Cardlytics, Inc. (NASDAQ:CDLX) Stock Holdings Increased by Bank of New York Mellon Corp

Bank of New York Mellon Corp boosted its holdings in Cardlytics, Inc. (NASDAQ:CDLX) by 15.4% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 135,924 shares of the company’s stock after buying an additional 18,179 shares during the quarter. Bank of New York Mellon Corp’s holdings in Cardlytics were worth $1,116,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. Jump Financial LLC acquired a new position in shares of Cardlytics in the 4th quarter worth $355,000. Brown Advisory Inc. increased its stake in Cardlytics by 1.7% in the 4th quarter. Brown Advisory Inc. now owns 199,633 shares of the company’s stock worth $1,839,000 after purchasing an additional 3,257 shares in the last quarter. Olympiad Research LP purchased a new position in Cardlytics in the 4th quarter worth about $247,000. Clear Street Markets LLC acquired a new stake in Cardlytics during the 4th quarter worth about $199,000. Finally, General Equity Holdings LP lifted its stake in Cardlytics by 31.0% during the fourth quarter. General Equity Holdings LP now owns 624,058 shares of the company’s stock valued at $5,748,000 after buying an additional 147,843 shares in the last quarter. Institutional investors own 68.10% of the company’s stock.

Insider Transactions at Cardlytics

In related news, insider Nicholas Hollmeyer Lynton sold 5,956 shares of Cardlytics stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $7.95, for a total value of $47,350.20. Following the completion of the sale, the insider now owns 78,593 shares of the company’s stock, valued at approximately $624,814.35. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, insider Nicholas Hollmeyer Lynton sold 5,956 shares of the stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $7.95, for a total transaction of $47,350.20. Following the transaction, the insider now owns 78,593 shares of the company’s stock, valued at approximately $624,814.35. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Alexis Desieno sold 7,451 shares of the business’s stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $7.95, for a total value of $59,235.45. Following the completion of the sale, the chief financial officer now owns 6,898 shares of the company’s stock, valued at $54,839.10. The disclosure for this sale can be found here. Insiders have sold a total of 43,613 shares of company stock worth $362,840 in the last 90 days. 4.40% of the stock is owned by insiders.

Cardlytics Stock Performance

Shares of CDLX stock opened at $3.67 on Friday. Cardlytics, Inc. has a fifty-two week low of $2.89 and a fifty-two week high of $20.52. The stock’s 50-day moving average is $5.33 and its two-hundred day moving average is $8.86. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.77 and a quick ratio of 1.77. The firm has a market cap of $179.03 million, a P/E ratio of -0.83 and a beta of 1.68.

Cardlytics (NASDAQ:CDLX) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.12. The firm had revenue of $69.64 million for the quarter, compared to the consensus estimate of $75.39 million. Cardlytics had a negative return on equity of 17.96% and a negative net margin of 50.21%. The firm’s revenue was down 9.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.57) earnings per share. Analysts predict that Cardlytics, Inc. will post -1.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on CDLX shares. Craig Hallum lowered shares of Cardlytics from a “buy” rating to a “hold” rating in a research note on Thursday, August 8th. Northland Capmk lowered Cardlytics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 16th. Needham & Company LLC lowered Cardlytics from a “buy” rating to a “hold” rating in a research report on Thursday, August 8th. Lake Street Capital cut Cardlytics from a “buy” rating to a “hold” rating and lowered their target price for the company from $18.00 to $5.00 in a research note on Thursday, August 8th. Finally, Northland Securities cut shares of Cardlytics from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $7.00 to $5.00 in a report on Friday, August 16th. One equities research analyst has rated the stock with a sell rating and five have given a hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $7.50.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.